Dr. Smith Discusses Novel CAR T-Cell Therapies for Myeloma

Video

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering (MSK) Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Smith says that he spends most of his time in the laboratory, where he makes novel CAR T-cell designs that are aimed at increasing persistence. In myeloma, the CAR T-cell therapy with the most data is bb2121, which has been studied in the relapsed population in US-based clinical trials.

Another novel therapy is JCARH125, which is progressing in clinical trials now, although the results have yet to be reported. JCARH125 is a human-derived CAR T-cell therapy, which may limit the patient's immune response against the CAR T cell, Smith explains.

Other things that are being looked at for the next generation of CAR T-cell therapies include targeting more than 1 target with the same CAR vector. At MSK, Smith and his colleagues have created “armored CAR T cells,” which are modified to not only encode for the CAR, but also for a second gene that encodes a protein. This gives the T cells a further advantage to eradicate the myeloma in the immunosuppressive microenvironment, Smith says.

Recent Videos
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
© 2025 MJH Life Sciences

All rights reserved.